Demographic and Clinical Factors Associated with Patient-Reported Remission in Psoriasis.

Area of Science:

• Dermatology
• Patient-Reported Outcomes
• Psoriasis Research

Background:

• Psoriasis remission is a key treatment goal, but definitions vary, impacting patient care.
• Current psoriasis treatment strategies sometimes focus solely on skin involvement, neglecting patient-reported quality of life.
• Understanding patient perspectives on remission is crucial for effective psoriasis management.

Purpose of the Study:

• To identify factors associated with patient-reported remission in psoriasis.
• To explore the relationship between psoriasis severity, quality of life, and patient perception of remission.
• To inform treat-to-target initiatives by incorporating patient-reported outcomes.

Main Methods:

• A survey of 1570 individuals with psoriatic disease was conducted by the National Psoriasis Foundation.
• Psoriasis severity was assessed using the Patient Report of Extent of Psoriasis Involvement (PREPI) for body surface area (BSA).
• Multivariate logistic regression analyzed factors associated with patient-reported remission, including Dermatology Life Quality Index (DLQI) and global quality of life (QoL).

Main Results:

• Over half (51.7%) of participants with BSA ≤3% reported psoriasis remission, lasting an average of 31 months.
• Psoriasis remission was independently associated with female sex, lower BSA, better DLQI and global QoL, biologic use, and psoriatic arthritis diagnosis.
• No association was found between remission and age, race, BMI, or number of comorbidities.

Conclusions:

• Patient perception of psoriasis remission is multifactorial, extending beyond body surface area.
• Quality of life and specific treatment types significantly influence a patient's sense of remission.
• These findings highlight the importance of a holistic approach to psoriasis management, incorporating patient-reported outcomes.